Philip Morris International Acquires Vectura Group plc

Philip Morris International Acquires Fertin Pharma from EQT Private Equity

July 1, 2021

Pharmaceuticals

Philip Morris International has agreed to acquire Fertin Pharma, a Denmark-headquartered specialist CDMO in oral and intra-oral delivery technologies, from EQT Private Equity for a headline enterprise value of DKK 5.1 billion. Fertin Pharma — which operates sites in Denmark, Canada and India and employs more than 860 people — will strengthen PMI's smoke-free and beyond-nicotine product capabilities; the transaction is subject to customary approvals.

Japan Tobacco (JT Group) Acquires Vector Group Ltd.

August 21, 2024

Consumer Products

Japan Tobacco Inc. (JT Group) acquired Vector Group Ltd. through a cash tender offer at $15.00 per share, representing approximately $2.4 billion of equity value. The transaction, effected by tender offer and a statutory merger (Vapor Merger Sub Inc.), makes Vector Group a wholly owned subsidiary of JT and expands JT’s presence and distribution network in the U.S. combustibles market.

Philip Morris Holland (PMHH) Acquires Majority Stake in Swedish Match

November 10, 2022

Consumer Products

Philip Morris Holland Holdings B.V. (an affiliate of Philip Morris International) declared its public offer for Swedish Match unconditional after receiving tenders representing ~82.6% of the share capital and subsequently purchased additional shares to reach ~85.9%. The offer priced shares at SEK 116 (reduced to SEK 115.07 for tenders in the extended period due to a dividend), with PMHH aiming to exceed 90% ownership to delist Swedish Match and integrate its oral nicotine portfolio with PMI’s IQOS business.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

H.I.G. Capital Acquires BioVectra Inc.

November 4, 2019

Pharmaceuticals

H.I.G. Capital, through an affiliate, completed the acquisition of BioVectra Inc., a Canadian contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), intermediates and biologics. The deal — a carve-out from Mallinckrodt — positions H.I.G. to support BioVectra's growth and further expand its manufacturing capabilities across Charlottetown, Prince Edward Island and Windsor, Nova Scotia.

22nd Century Group Acquires RX Pharmatech Ltd

January 24, 2023

Food & Beverage

22nd Century Group, through its GVB Biopharma business, acquired UK-based RX Pharmatech Ltd, a distributor of cannabinoid/CBD products and holder of numerous U.K. novel food applications. The deal includes $650,000 up-front in cash and stock plus a three-year equity earn-out tied to revenue milestones and aims to strengthen 22nd Century's access and distribution in the U.K. and EU consumer CBD market.